Injecting Risk Into Prison Sentences

Published date01 September 2011
DOI10.1177/0032885511409893
Date01 September 2011
AuthorKevin Denys Bonnycastle,Charles Villebrun
The Prison Journal
91(3) 325 –346
© 2011 SAGE Publications
Reprints and permission:
sagepub.com/journalsPermissions.nav
DOI: 10.1177/0032885511409893
http://tpj.sagepub.com
409893TPJ91310.1177/0032885511409893B
onnycastle and VillebrunThe Prison Journal
© 2011 SAGE Publications
Reprints and permission:
sagepub.com/journalsPermissions.nav
1Saint Mary’s University, Halifax, Nova Scotia, Canada
2Charles Villebrun is a federal Canadian prisoner serving a life sentence
The Prison Journal is saddened by
the recent death of Dr.
Bonnycastle and is honored to
publish her last research article.
Injecting Risk Into Prison
Sentences:
A Quantitative Analysis
of a Prisoner-Driven
Survey to Measure
HCV/HIV Seroprevalence,
Risk Practices, and Viral
Testing at One Canadian
Male Federal Prison
Kevin Denys Bonnycastle1
and Charles Villebrun2
Abstract
This article draws on penal epidemiological studies to analyze data from a
prisoner-driven survey measuring HCV/HIV seroprevalence and risk behaviors
in one Canadian male prison. Our data illuminate confounding points of
potential blood exchange among injectors and noninjectors, HCV/HIV car-
riers and noncarriers, tested and untested prisoners, and prison and free
326 The Prison Journal 91(3)
community members. The survey finds higher HCV/HIV incidence and testing
rates among injectors, and a penal population educated about high-risk prac-
tices. This study includes the first point-in-time estimate by penal injectors
on the number and condition of needles/syringes, identifying an overlooked
HCV conduit: the transfer of abandoned syringe components to new(er)
syringes.
Keywords
HCV/HIV seroprevalence, risk behaviors, prison needles/syringes
Few journal publications explore the health damage wrought by Western
systems of punishment generally and penal antidrug strategies specifically.
Although some medical journals—particularly, the British Medical Journal
have published in the area of hepatitis C (HCV) and human immunodeficiency
virus (HIV) prevalence and transfer in prison populations, elsewhere, the penal
policies and practices that sustain viral transfer—are not a widespread object
of investigation, notwithstanding some exceptions (Chu & Elliott, 2009; Krebs,
2002). With reference to extant penal epidemiological studies, this article
analyzes findings from a quantitative prisoner-driven survey measuring HCV/
HIV seroprevalence and risk behaviors in one Canadian male prison operated
by the Correctional Service of Canada (CSC). The CSC has responsibility for
approximately 13,000 federally sentenced males and females serving 2 or more
years. The study also includes the first reported point-in-time estimate by penal
injectors on the number and condition of needles and syringes.
The survey was spearheaded by two prisoner peer education counselors
(hereafter, “PEC”)—holding the institutional job titles of Harm Reduction and
Assistant Harm Reduction Coordinators—acting with the consent and support
of the elected members of that prison’s inmate committee. The survey’s goals
were practical and twofold: first, that the questionnaire in and of itself would
encourage prisoners to become more self-reflective regarding their high-risk
and viral testing practices and, second, that the data, once tabulated and dis-
seminated, would motivate prisoners to seek regular viral (re)testing. In light
of these objectives, rather than constructing a multiple regression model to
isolate independent variables associated with HCV/HIV seropositivity, this
survey represents a snapshot over one time period of the prevalence of HCV/
HIV, viral testing, risk behaviors, and the multiple and intersecting avenues
for transmitting HCV/HIV within this prison and beyond.

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT